STOCK TITAN

Disc Medicine, Inc. - IRON STOCK NEWS

Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of hematologic diseases through innovative therapies. The company is primarily focused on manipulating the hepcidin pathway, which is the master regulator of iron metabolism, to address ineffective red blood cell production in various hematologic conditions. By leveraging new insights into hepcidin biology, Disc Medicine strives to bring hope and improved quality of life to patients who suffer from serious blood disorders.

Disc Medicine is currently advancing several first-in-class therapeutic candidates that target fundamental red blood cell biology pathways, including heme biosynthesis and iron homeostasis. Among its leading candidates is DISC-0974, an investigational monoclonal antibody designed to suppress hepcidin production by inhibiting the hemojuvelin (HJV) co-receptor. This novel treatment has shown promising results in reducing serum hepcidin and increasing serum iron levels, leading to improvements in hemoglobin and reduced transfusion burdens in myelofibrosis (MF) patients with anemia.

The company also boasts bitopertin, an orally administered GlyT1 inhibitor that modulates heme biosynthesis. Bitopertin has demonstrated significant efficacy in reducing PPIX levels and improving sunlight tolerance in patients with erythropoietic protoporphyria (EPP) during the phase 2 BEACON study. Disc Medicine is actively working on further trials to solidify these findings and expand its therapeutic applications.

On the financial front, Disc Medicine is well-supported by a robust pipeline of both clinical and preclinical candidates aimed at transforming the landscape of hematologic treatments. Recently, the company presented compelling data at the 65th American Society of Hematology (ASH) Annual Meeting, showcasing the potential of its portfolio. Their commitment to advancing these therapies is evident from their ongoing and upcoming clinical trials, including the phase 1b/2a study of DISC-0974 in chronic kidney disease (CKD) patients with anemia and the phase 1 study of DISC-3405 in healthy volunteers.

Disc Medicine continues to foster strategic partnerships and collaborations to accelerate the development and commercialization of its products. The company's vision is to address unmet medical needs in hematology and deliver innovative therapies that can change the standard of care for patients globally.

Rhea-AI Summary
Disc Medicine, Inc. appoints Jean Franchi as Chief Financial Officer and promotes Jonathan Yu to Chief Operating Officer. Franchi brings over 30 years of finance leadership experience in biotech companies, and Yu has been involved in key business roles at the company. The company expresses excitement about important data read-outs for their programs in 2024 and the potential for late-stage development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
management
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the retirement of Chief Innovation Officer, Dr. Brian MacDonald, after a distinguished 28-year career. Dr. MacDonald will transition to become Chair of Disc’s Scientific Advisory Board. The company expressed gratitude for his leadership and contributions, with plans for him to continue leading as part of the Scientific Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
management
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) presented updated results from the phase 2 open-label BEACON study of bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, in patients with erythropoietic protoporphyria (EPP) as an oral presentation at the 65th ASH Annual Meeting. The data showed significant reductions in protoporphyrin IX (PPIX) > 40%, improvements in sunlight tolerance, and positive results from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) has announced data from initial dose cohorts of its ongoing phase 1b/2 study of DISC-0974, a monoclonal antibody designed to suppress hepcidin by inhibiting the hemojuvelin (HJV) co-receptor, in MF patients with anemia. The initial data demonstrated that treatment with DISC-0974 substantially decreased serum hepcidin, increased serum iron, and resulted in improvements in hemoglobin or reduced transfusion burden across a broad range of MF patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the issuance of patent No. 11,813,257 by the USPTO for methods of treating erythropoietic protoporphyrias (EPPs) with glycine transport inhibitors. The patent covers the use of bitopertin, a glycine transport inhibitor, in treating EPP or XLP, with an anticipated expiration in 2041. This further secures IP protection for bitopertin, demonstrating Disc's innovative approach to treating EPP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) reported the completion of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP), with data from all adult patients in BEACON to be presented at ASH 2023. Preliminary pharmacodynamic data from the ongoing phase 1b/2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia will also be presented. Additionally, they initiated a Phase 1 trial of DISC-3405, an anti-TMPRSS6 antibody, and received fast track designation by the FDA for the treatment of polycythemia vera (PV). Financial results for the third quarter ended September 30, 2023, were also reported, with cash and cash equivalents of $370.5 million, increased R&D and G&A expenses, and a net loss of $14.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announces participation in fireside chats at Stifel 2023 Healthcare Conference and presentations at Jefferies London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts available on ir.discmedicine.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
Rhea-AI Summary
Disc Medicine, Inc. has completed enrollment for the phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP). The company will present updated interim data from the BEACON study at the upcoming ASH meeting, including a preliminary analysis of the pivotal endpoint. They will also present preliminary data on pharmacodynamic activity from the phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia. The enrollment for both studies was completed in under a year. The company will host a conference call on December 11th to discuss the data and operational plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
Rhea-AI Summary
Disc Medicine's Chief Financial Officer, Joanne Bryce, plans to leave the company. A search for a successor has been initiated. Bryce will remain in her role until a replacement is found.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none

FAQ

What is the current stock price of Disc Medicine (IRON)?

The current stock price of Disc Medicine (IRON) is $58.17 as of November 4, 2024.

What is the market cap of Disc Medicine (IRON)?

The market cap of Disc Medicine (IRON) is approximately 1.7B.

What is Disc Medicine, Inc. focused on?

Disc Medicine, Inc. is focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases by targeting fundamental pathways of red blood cell biology.

What is DISC-0974?

DISC-0974 is an investigational monoclonal antibody designed to suppress hepcidin production and increase serum iron levels in patients suffering from anemia of inflammation.

What are the recent achievements of Disc Medicine?

Recently, Disc Medicine presented promising data on DISC-0974 and bitopertin at the 65th American Society of Hematology (ASH) Annual Meeting, indicating significant progress in their clinical trials.

What is bitopertin?

Bitopertin is an orally administered GlyT1 inhibitor designed to modulate heme biosynthesis, currently in phase 2 trials for treating erythropoietic protoporphyria (EPP).

What are the main research areas of Disc Medicine?

Disc Medicine focuses on heme biosynthesis and iron homeostasis pathways to develop treatments for a wide range of hematologic diseases.

Who are the targeted patients for DISC-0974?

DISC-0974 targets patients with myelofibrosis (MF) and severe anemia, including those dependent on blood transfusions.

What does the phase 1b/2a study of DISC-0974 involve?

The phase 1b/2a study of DISC-0974 involves enrolling patients with MF and severe anemia to assess safety, tolerability, and markers of iron regulation and hematologic parameters.

How does Disc Medicine plan to advance its therapies?

Disc Medicine plans to advance its therapies through ongoing and upcoming clinical trials, strategic partnerships, and collaborations to accelerate development and commercialization.

What is the significance of hepcidin in hematologic diseases?

Hepcidin is the master regulator of iron metabolism and plays a crucial role in anemia of inflammation, making it a significant target for therapeutic intervention in hematologic diseases.

How can I get more information about Disc Medicine's updates?

You can visit Disc Medicine's website at www.discmedicine.com for the latest updates and detailed information about their ongoing projects and clinical trials.

Disc Medicine, Inc.

Nasdaq:IRON

IRON Rankings

IRON Stock Data

1.71B
29.73M
12.49%
98.43%
4.97%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WATERTOWN